ACTINIUM PHARMACEUTICALS INC (ATNM) Fundamental Analysis & Valuation

NYSEARCA:ATNM • US00507W2061

Current stock price

1.17 USD
0 (0%)
Last:

This ATNM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ATNM Profitability Analysis

1.1 Basic Checks

  • In the past year ATNM has reported negative net income.
  • In the past year ATNM has reported a negative cash flow from operations.
  • ATNM had negative earnings in each of the past 5 years.
  • ATNM had negative operating cash flow in 4 of the past 5 years.
ATNM Yearly Net Income VS EBIT VS OCF VS FCFATNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M

1.2 Ratios

  • ATNM has a worse Return On Assets (-65.45%) than 62.09% of its industry peers.
  • Looking at the Return On Equity, with a value of -432.56%, ATNM is doing worse than 75.82% of the companies in the same industry.
Industry RankSector Rank
ROA -65.45%
ROE -432.56%
ROIC N/A
ROA(3y)-58.37%
ROA(5y)-46.97%
ROE(3y)-227.83%
ROE(5y)-153.37%
ROIC(3y)N/A
ROIC(5y)N/A
ATNM Yearly ROA, ROE, ROICATNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ATNM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATNM Yearly Profit, Operating, Gross MarginsATNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ATNM Health Analysis

2.1 Basic Checks

  • ATNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ATNM has about the same amout of shares outstanding than it did 1 year ago.
  • ATNM has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ATNM has been reduced compared to a year ago.
ATNM Yearly Shares OutstandingATNM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
ATNM Yearly Total Debt VS Total AssetsATNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • ATNM has an Altman-Z score of -11.93. This is a bad value and indicates that ATNM is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -11.93, ATNM is not doing good in the industry: 76.40% of the companies in the same industry are doing better.
  • There is no outstanding debt for ATNM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.93
ROIC/WACCN/A
WACC9.21%
ATNM Yearly LT Debt VS Equity VS FCFATNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • ATNM has a Current Ratio of 6.20. This indicates that ATNM is financially healthy and has no problem in meeting its short term obligations.
  • ATNM has a better Current ratio (6.20) than 63.06% of its industry peers.
  • A Quick Ratio of 6.20 indicates that ATNM has no problem at all paying its short term obligations.
  • ATNM has a Quick ratio of 6.20. This is in the better half of the industry: ATNM outperforms 63.44% of its industry peers.
Industry RankSector Rank
Current Ratio 6.2
Quick Ratio 6.2
ATNM Yearly Current Assets VS Current LiabilitesATNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ATNM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 14.17% over the past year.
  • Measured over the past years, ATNM shows a very negative growth in Revenue. The Revenue has been decreasing by -55.63% on average per year.
EPS 1Y (TTM)14.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.76%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-55.63%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 16.08% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 369.42% on average over the next years. This is a very strong growth
EPS Next Y18.59%
EPS Next 2Y22%
EPS Next 3Y12.06%
EPS Next 5Y16.08%
Revenue Next Year-100%
Revenue Next 2Y2078.07%
Revenue Next 3Y843.37%
Revenue Next 5Y369.42%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ATNM Yearly Revenue VS EstimatesATNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
ATNM Yearly EPS VS EstimatesATNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

0

4. ATNM Valuation Analysis

4.1 Price/Earnings Ratio

  • ATNM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ATNM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATNM Price Earnings VS Forward Price EarningsATNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATNM Per share dataATNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ATNM's earnings are expected to grow with 12.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22%
EPS Next 3Y12.06%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ATNM Dividend Analysis

5.1 Amount

  • No dividends for ATNM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATNM Fundamentals: All Metrics, Ratios and Statistics

ACTINIUM PHARMACEUTICALS INC

NYSEARCA:ATNM (4/8/2026, 8:17:00 PM)

1.17

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30
Earnings (Next)05-07
Inst Owners20.62%
Inst Owner Change0%
Ins Owners2.36%
Ins Owner Change0%
Market Cap36.70M
Revenue(TTM)90.00K
Net Income(TTM)-33.89M
Analysts81.82
Price Target5.1 (335.9%)
Short Float %3.45%
Short Ratio8.69
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.22%
Min EPS beat(2)-5.04%
Max EPS beat(2)51.49%
EPS beat(4)2
Avg EPS beat(4)1.16%
Min EPS beat(4)-80.18%
Max EPS beat(4)51.49%
EPS beat(8)5
Avg EPS beat(8)11.4%
EPS beat(12)8
Avg EPS beat(12)10.09%
EPS beat(16)9
Avg EPS beat(16)-3.47%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-6.66%
EPS NQ rev (3m)-93.94%
EPS NY rev (1m)0%
EPS NY rev (3m)8.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 407.81
P/FCF N/A
P/OCF N/A
P/B 4.69
P/tB 4.69
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -65.45%
ROE -432.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.37%
ROA(5y)-46.97%
ROE(3y)-227.83%
ROE(5y)-153.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.12%
Cap/Sales 115.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.2
Quick Ratio 6.2
Altman-Z -11.93
F-Score4
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)28.36%
Cap/Depr(5y)32.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.76%
EPS Next Y18.59%
EPS Next 2Y22%
EPS Next 3Y12.06%
EPS Next 5Y16.08%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-55.63%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y2078.07%
Revenue Next 3Y843.37%
Revenue Next 5Y369.42%
EBIT growth 1Y13.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.86%
EBIT Next 3Y-9.01%
EBIT Next 5YN/A
FCF growth 1Y25.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.68%
OCF growth 3YN/A
OCF growth 5YN/A

ACTINIUM PHARMACEUTICALS INC / ATNM Fundamental Analysis FAQ

What is the fundamental rating for ATNM stock?

ChartMill assigns a fundamental rating of 3 / 10 to ATNM.


Can you provide the valuation status for ACTINIUM PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to ACTINIUM PHARMACEUTICALS INC (ATNM). This can be considered as Overvalued.


What is the profitability of ATNM stock?

ACTINIUM PHARMACEUTICALS INC (ATNM) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ACTINIUM PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ACTINIUM PHARMACEUTICALS INC (ATNM) is expected to grow by 18.59% in the next year.